Cogent Biosciences, Inc. current report, 18 June 2019

Full document

Business Context and Reporting Period

This Form 8-K filing reports on the Annual Meeting of Stockholders held by Unum Therapeutics Inc. (Note: The request metadata listed "Cogent Biosciences, Inc.", but the filing text explicitly identifies the registrant as Unum Therapeutics Inc.) on June 18, 2019. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol UMRX.

Key Financial Metrics

This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes and Voting Results

The filing details the results of two proposals submitted to stockholders. All matters were approved.

  • Shareholder Participation: Of 30,118,822 shares entitled to vote, 24,438,348 shares were present or represented by proxy.
  • Proposal 1: Election of Class I Director
    • Nominee: Karen Ferrante
    • Votes For: 20,318,680
    • Votes Withheld: 2,229,287
    • Broker Non-Votes: 1,890,381
    • Outcome: Elected to serve until the 2022 annual meeting.
  • Proposal 2: Ratification of Independent Auditor
    • Auditor: PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2019.
    • Votes For: 24,437,672
    • Votes Against: 601
    • Abstentions: 75
    • Broker Non-Votes: None
    • Outcome: Ratified.

Guidance, Outlook, and Risks

The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It references a Proxy Statement filed on April 30, 2019, for detailed descriptions of the proposals.

Important Facts for Investor Verification

  • Verify the correct registrant name is Unum Therapeutics Inc., not Cogent Biosciences, Inc.
  • Confirm the election of Karen Ferrante as a Class I director.
  • Note the ratification of PricewaterhouseCoopers LLP as the independent auditor for the 2019 fiscal year.
  • Review the April 30, 2019 Proxy Statement for detailed background on the director nominee and auditor appointment.